Pancreatic Cystic LesionsNCT01711294
Evaluation of PCLs Using Three EUS-FNA Needles
A study testing 19 G Flex Needle, 22 G Needle and 19 G Needle in people with Pancreatic Cystic Lesions, run by Boston Scientific Corporation at 8 sites in 3 countries.
Trial summary
To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cystic Lesions
- What is being tested?
- 19 G Flex Needle, 22 G Needle and 19 G Needle
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 8 sitesin 3 countries
- Study dates
- 8 Jan 2013to 18 Dec 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pancreatic cystic lesion measuring 13mm or greater in largest diameter.
- Indicated for EUS evaluation of the PCL including EUS-FNA.
- Age 18 years of age or older.
- Willing and able to comply with the study procedures and provide written informed consent form to participate in the study.
Who cannot join
- Cysts in which FNA is not indicated based on review by the clinician, including potential concern of blood vessel location relative to the cyst.
- Requirement for anticoagulation using clopidogril, warfarin, or other long acting antiplatelet agents (with the exception of aspirin) that cannot be safely stopped according to institutional guidelines.
- Standard contraindications for EUS.
- Known pancreatic pseudocyst.
- Pregnancy.
Trial locations and contacts
8 sites in 3 countries.
8 sites in 3 countries
United States6 sites
Massachusetts General Hospital
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Indiana University Medical Center
Indianapolis, Indiana, 46202
Mayo Clinic
Jacksonville, Florida, 32224
New York Presbyterian Hospital/Columbia University Medical Center
New York, New York, 10032
Mayo Clinic
Scottsdale, Arizona, 85259
About this study
Official title: A Multicenter, Prospective, Randomized Study on Endosonographic Evaluation of Pancreatic Cystic Lesions Using 22 G, 19 G, and Flexible 19 G Fine Needle Aspiration
To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.
- Conditions
- Pancreatic Cystic Lesions
- Being tested
- 19 G Flex Needle, 22 G Needle, 19 G Needle
- Keywords
- Pancreatic Cystic Lesions, PCL, EUS-FNA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
19 G Flex NeedleDevice
Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
22 G NeedleDevice
Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
19 G NeedleDevice
Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
| Study group | Role | What they receive |
|---|---|---|
| 19 G Flex Needle | Active comparator | Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex) Receives: Device: 19 G Flex Needle |
| 22 G Needle | Active comparator | Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G) Receives: Device: 22 G Needle |
| 19 G Needle | Active comparator | Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G) Receives: Device: 19 G Needle |
What is being measured
The primary outcome is the main question the study is designed to answer.
Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume
Volume of aspirated cyst fluid as a function of estimated maximal volume, based on pre-aspiration EUS measure of cyst diameter (s) (% aspiration of total estimated volume)
Measured: At procedure (Up to 1 hour)
Secondary outcomes (15)
Number of Patients With Related Adverse Events
Adverse events related to study procedure or study device were tabulated. Adverse events were assessed from the index procedure up to 30 days post procedure.
Measured: 30 days
Change in Volume of Cyst Post Initial Procedure Compared to Pre Procedure
Change value is calculated as cyst volume measured after initial procedure (up to 1 hour) minus volume measured at the beginning of the initial procedure. Volume is measured using the standard geometric formula 4/3 πr³ where r is half the long axis. The volume unit is cc.
Measured: Procedure (Up to 1 hour)
Number of Participants With Successful Echoendoscopic Fine Needle Aspiration of PCL
Successful echoendoscopic fine needle aspiration of PCL, defined as complete cyst aspiration (final cyst maximal diameter of less than 5mm) or collection of aspirate adequate to perform two standard assays: cytology and carcinoembryonic antigen (CEA) (sample volume of 3 cc or more)
Measured: Procedure (up to 1 hour)
Number of Participants With PCL Reached/Penetrated
Patients whose pancreatic cyst lesion(s) can be reached and penetrated by the EUS-FNA needles.
Measured: Procedure (Up to 1 hour)
Number of EUS-FNA Needle Passes at Initial Procedure.
Needle pass defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst.
Measured: Procedure (Up to 1 hour)
Number of EUS-FNA Needles Used at Initial Procedure.
Total number of EUS-FNA needles used across all participants at the initial procedure.
Measured: Procedure (Up to 1 hour)
Time Needed for Aspiration for Each Needle Pass at Initial Procedure.
Needle pass is defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst.
Time of needle pass in is time of the first needle puncture into the cyst lumen. Needle pass out is time of removal of needle outside the cyst lumen, or after 10 seconds of failed attempt to aspirate fluid after the last needle re-repositioning in a single or multi-compartment cyst.
Measured: Procedure (Up to 1 hour)
Time From First Needle Pass in to Last Needle Pass Out at Initial Procedure.
Needle pass is defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst. Time of first needle pass in is time of the first needle puncture into the cyst lumen. Time of last needle pass out is time of removal of needle outside the cyst lumen at the end of the last fluid aspiration from a single or multi-loculated cyst, or after 10 seconds of failed attempt to aspirate fluid after the last needle re-repositioning in a single or multi-compartment cyst.
Measured: Procedure (Up to 1 hour)
Number of Needles With Needle Insertion Rated as Excellent/Very Good
Number of needles rated either Excellent or Very good when inserted into the echoendoscope at the initial procedure.
Measured: Procedure (Up to 1 hour)
Number of Needles With Needle Removal Rated as Excellent/Very Good
Number of needles rated either Excellent or Very good when removed from the echoendoscope at the initial procedure.
Measured: Procedure (Up to 1 hour)
Number of Needles With Needle Visualization Rated as Excellent/Very Good
Number of needles rated either Excellent or Very good for visualization at the initial procedure.
Measured: Procedure (Up to 1 hour)
Number of Participants With Accurate Diagnosis of the Disease State Using the EUS-FNA Needles
In order to assess the accuracy of EUS-FNA-based standard assays (cytology and CEA) as a diagnostic measure of disease state, the Disease State per EUS-FNA measure was compared to a reference diagnosis. The reference diagnostic standard was diagnosis from a surgical specimen histology, the true gold standard for cases that evolved to surgical resection within the follow-up of the study. For cases that did not progress to surgery within the follow-up period, the reference diagnostic standard was a composite diagnosis by a consensus board. The consensus board consisted of 3 experts who were blinded to the type of needle used. The consensus board diagnoses of disease state were based on baseline medical history, EUS and cross sectional imaging of the cyst, and aspirate characteristics (i.e. aspirate color and viscosity). If the EUS-FNA diagnosis matches with the histopathology or consensus board diagnosis, then the participant will be counted as having accurate diagnosis.
Measured: up to 2 years
Number of Participants Requiring Post EUS-FNA Patient Management
Post EUS-FNA patient management required (clinical and/or imaging surveillance, percutaneous drainage, surgical removal).
Measured: 30 days
Number of Participants Whose Management Decision Was Directly Influenced by the EUS Findings
Patients whose Post EUS-FNA Management (clinical and/or imaging surveillance, percutaneous drainage, surgical removal) was Directly Influenced by the EUS-FNA findings.
Measured: Procedure - 30 days after procedure
Rate of Cross-over to Salvage Arm
In the case of inability to access the pancreatic cystic lesion or to attain complete cyst aspiration, salvage aspiration procedure should be performed. Patients randomized to 19G Flex should undergo a salvage procedure with 22G or 19G needle (needle choice at discretion of physician); patients randomized to 22G or 19G should undergo salvage procedure with 19G Flex needle.
Measured: Procedure (Immediate)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2012 (estimated)
- Study start8 Jan 2013
- Primary completion6 Jun 2017
- Study completion18 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pancreatic Cystic LesionsStudies of the same condition, open and under way.
- More trials run by Boston Scientific CorporationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boston Scientific Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michael B Wallace, MD,MPH, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01711294
- Sponsor's protocol ID
- 90869947
- Other IDs
- E7084
- Status last verified
- Jan 2021
- First submitted
- 26 Sep 2012
- Last updated
- 15 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Al-Haddad M, Wallace MB, Brugge W, Lakhtakia S, Li ZS, Sethi A, Pleskow D, Nguyen CC, Pannala R, DeWitt J, Raimondo M, Woodward TA, Ramchandani MJ, Jin Z, Xu C, Faigel DO. Fine-needle aspiration of pancreatic cystic lesions: a randomized study with long-term follow-up comparing standard and flexible needles. Endoscopy. 2021 Nov;53(11):1132-1140. doi: 10.1055/a-1311-9927. Epub 2021 Feb 4.
PubMed 33197941
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Prospective, Randomized Study on Endosonographic Evaluation of Pancreatic Cystic Lesions Using 22 G, 19 G, and Flexible 19 G Fine Needle Aspiration
- ClinicalTrials.gov ID
- NCT01711294
- Acronym / sponsor ID
- 90869947
- Conditions
- Pancreatic Cystic Lesions
- Keywords
- Pancreatic Cystic Lesions, PCL, EUS-FNA
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- Boston Scientific CorporationIndustry (pharma, biotech, devices)
- Study start
- 8 Jan 2013 (actual)
- Primary completion
- 6 Jun 2017 (actual)
- Study completion
- 18 Dec 2019 (actual)
- First posted
- 22 Oct 2012 (estimated)
- Results
- Posted 12 Nov 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 19 G Flex Needle | Active comparator | Device: 19 G Flex NeedleDevice: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex) |
| 22 G Needle | Active comparator | Device: 22 G NeedleDevice: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G) |
| 19 G Needle | Active comparator | Device: 19 G NeedleDevice: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Pancreatic cystic lesion measuring 13mm or greater in largest diameter.
- Indicated for EUS evaluation of the PCL including EUS-FNA.
- Age 18 years of age or older.
- Willing and able to comply with the study procedures and provide written informed consent form to participate in the study.
Key exclusion criteria (5 listed)
- Cysts in which FNA is not indicated based on review by the clinician, including potential concern of blood vessel location relative to the cyst.
- Requirement for anticoagulation using clopidogril, warfarin, or other long acting antiplatelet agents (with the exception of aspirin) that cannot be safely stopped according to institutional guidelines.
- Standard contraindications for EUS.
- Known pancreatic pseudocyst.
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 19 G Flex NeedleFine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle. | Device | 19 G Flex Needle |
| 22 G NeedleFine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle. | Device | 22 G Needle |
| 19 G NeedleFine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle. | Device | 19 G Needle |
Primary outcome
Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume
Time frame: At procedure (Up to 1 hour)
Volume of aspirated cyst fluid as a function of estimated maximal volume, based on pre-aspiration EUS measure of cyst diameter (s) (% aspiration of total estimated volume)
15 secondary outcomes
Number of Patients With Related Adverse Events
Time frame: 30 days
Change in Volume of Cyst Post Initial Procedure Compared to Pre Procedure
Time frame: Procedure (Up to 1 hour)
Number of Participants With Successful Echoendoscopic Fine Needle Aspiration of PCL
Time frame: Procedure (up to 1 hour)
Number of Participants With PCL Reached/Penetrated
Time frame: Procedure (Up to 1 hour)
Number of EUS-FNA Needle Passes at Initial Procedure.
Time frame: Procedure (Up to 1 hour)
Number of EUS-FNA Needles Used at Initial Procedure.
Time frame: Procedure (Up to 1 hour)
Time Needed for Aspiration for Each Needle Pass at Initial Procedure.
Time frame: Procedure (Up to 1 hour)
Time From First Needle Pass in to Last Needle Pass Out at Initial Procedure.
Time frame: Procedure (Up to 1 hour)
Number of Needles With Needle Insertion Rated as Excellent/Very Good
Time frame: Procedure (Up to 1 hour)
Number of Needles With Needle Removal Rated as Excellent/Very Good
Time frame: Procedure (Up to 1 hour)
Number of Needles With Needle Visualization Rated as Excellent/Very Good
Time frame: Procedure (Up to 1 hour)
Number of Participants With Accurate Diagnosis of the Disease State Using the EUS-FNA Needles
Time frame: up to 2 years
Number of Participants Requiring Post EUS-FNA Patient Management
Time frame: 30 days
Number of Participants Whose Management Decision Was Directly Influenced by the EUS Findings
Time frame: Procedure - 30 days after procedure
Rate of Cross-over to Salvage Arm
Time frame: Procedure (Immediate)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33197941Al-Haddad M, Wallace MB, Brugge W, Lakhtakia S, Li ZS, Sethi A, Pleskow D, Nguyen CC, Pannala R, DeWitt J, Raimondo M, Woodward TA, Ramchandani MJ, Jin Z, Xu C, Faigel DO. Fine-needle aspiration of pancreatic cystic lesions: a randomized study with long-term follow-up comparing standard and flexible needles. Endoscopy. 2021 Nov;53(11):1132-1140. doi: 10.1055/a-1311-9927. Epub 2021 Feb 4.
Related trials for Pancreatic Cystic Lesions
Not yet recruiting
Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function
Cystic Fibrosis
RecruitingObservational study
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer, Chronic Pancreatitis
RecruitingObservational study
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Pancreatic Cyst
RecruitingObservational study
UCSF PANC Cyst Registry
Pancreatic Cyst, Pancreatic Neoplasms
RecruitingObservational study
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
Breast Cancer, Benign Breast Condition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael B Wallace, MD,MPH principal investigator
Mayo Clinic
8 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 19 G Flex Needle, 22 G Needle and 19 G Needle in people with Pancreatic Cystic Lesions, run by Boston Scientific Corporation at 8 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States, China, India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Nov 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume (time frame: At procedure (Up to 1 hour)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01711294, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2021.